Intrepid USA: More Therapy, Longer Care, One Shared Settlement

In the Intrepid USA home health fraud settlement, the company agreed to pay $3,850,000 to resolve allegations of unnecessary therapy, improperly extended home health care and ineligible hospice care. The home health allegations turn on decisions an insider would recognize: how much therapy to provide and when to keep a patient on service.

Intrepid USA Healthcare Services operated a nationwide home health and hospice business from its Dallas headquarters. The Justice Department announced the settlement on August 20, 2024, saying the amount reflected Intrepid’s ability to pay. One payment resolved a Kentucky home health qui tam case and a separate Minnesota hospice whistleblower case.

What the Intrepid Home Health Allegations Covered

The government’s settlement agreement identifies two home health practices allegedly used to maximize reimbursement: medically unnecessary therapy within high-visit episodes and inappropriately extending care. The public announcement described a broader set of allegations involving 19 home healthcare facilities between 2016 and 2021. The government alleged that patients did not qualify or lacked proper certification, services were not reasonable or medically necessary, untrained staff provided services, or billed services never happened. The agreement’s account of the home health whistleblowers’ allegations also names unlicensed staff.

The settlement’s home health terms focus specifically on therapy volume and continued care. That focus matters to someone who remembers the visits being scheduled, the clinical reasons for continuing them, and the claims that followed.

Medicare home health eligibility requires homebound status and a qualifying need for skilled care. Under Medicare’s homebound test, illness or injury must make assistance, special transportation or a medical restriction relevant to leaving home. The patient normally cannot leave home, and doing so requires considerable and taxing effort.

Therapy Episodes With Twenty or More Visits

The government alleged that Intrepid provided medically unnecessary therapy to maximize reimbursement, limiting this part of the settlement to patients who received 20 or more therapy visits in an episode. The covered therapy locations were in Arkansas, Iowa, Kentucky, Minnesota, Tennessee, Texas, Virginia and Washington.

Improperly Extended Home Health Care

The government separately alleged that Intrepid inappropriately extended home health services to maximize reimbursement. The extended-care locations were in Arkansas, Kentucky, Louisiana and Tennessee.

For an insider, the distinction is practical. The therapy allegation concerns the amount of treatment within an episode. The extended-care allegation concerns the decision to continue services. The clinical record has to explain both the visits and the continuing need for care.

Why the Twenty-Visit Figure Matters

Medicare’s former home health payment system tied reimbursement to therapy-visit categories within a 60-day episode. In 2019, the highest therapy-volume category was 20 or more visits. That gave the visit count a financial significance beyond the therapist’s schedule.

The payment rules that established the Patient-Driven Groupings Model changed that structure effective January 1, 2020. Medicare moved to 30-day payment periods and removed therapy-volume payment thresholds. Patient characteristics, including clinical grouping, functional impairment and comorbidities, became the basis for grouping those periods.

The agreement’s therapy periods also reach past that change: Sweetwater, Tennessee, is covered from 2016 through 2021, and Bartlett, Tennessee, in 2018 and 2020 through 2021. For those later periods, the allegation remains medically unnecessary therapy provided to maximize reimbursement.

We see the problem in the government’s allegation plainly: the reimbursement goal was allegedly driving care that patients did not need. Medicare was supposed to be paying for their treatment. A visit count serving the agency’s revenue target puts that relationship backward.

The Hospice Case Had Its Own Patients and Facilities

The Minnesota case concerned eligibility for the Medicare hospice benefit. The government alleged that Intrepid admitted patients without a prognosis of six months or less to live if their illness ran its normal course, or continued serving patients who should have been discharged because they no longer qualified. The hospice terms in the agreement narrow that allegation to beneficiaries who received at least one year of hospice care at three locations, in Minnesota, Missouri and South Carolina.

The hospice case began with a former travel nurse and a former director of quality assessment, performance improvement and new business development. The home health case came from a former director of clinical excellence and integrity and a former regional manager of clinical excellence.

One Settlement Based on Ability to Pay

The settlement covered both service lines together, and the government based the amount on Intrepid’s ability to pay. The agreement says the government relied on financial disclosures the company provided and updated before the settlement. We see the imbalance: years of alleged billing for care patients did not need, followed by a settlement tied to what Intrepid could afford while it denied the allegations.

The agreement assigned a separate share of the recovery to each whistleblower group. It placed the home health whistleblowers’ share with the Kentucky case and the hospice whistleblowers’ share with the Minnesota case.

The Justice Department’s Civil Division and the U.S. Attorney’s Offices for the Western District of Kentucky and the District of Minnesota handled the investigation and resolution. The Department of Health and Human Services Office of Inspector General assisted in the investigations. The settled claims concerned Intrepid’s Medicare billing.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The agreement assigned separate shares of the recovery to the home health and hospice whistleblower groups.

What Evidence Is Needed to Prove Fraud?

For unnecessary therapy or extended care, the evidence connects the patient’s clinical needs, the care plan, the services recorded and the agency’s Medicare claims. The question behind Intrepid’s alleged reimbursement motive is who decided on the care and what information supported that decision.

The care plan identifies the disciplines involved and patient-specific services. Continuing care also involves recertification and plan review at least every 60 days. The shorter payment period introduced with the new model did not shorten that certification cycle.

Those records make different parts of the story visible. A therapist may know what treatment the patient needed. A clinical reviewer may know why the agency kept the patient on service. Billing staff may know how the visits and continuing episodes appeared in submitted claims. We connect those accounts to the same patient’s records and to the decisions that produced the bill.

Where the issue involves changes to the patient’s assessment, the original findings and later revisions help explain the payment inputs. For extended care, the continuing-care decision has to be read alongside the clinical support for it. The employee who understood the care can explain a conflict that the claim alone leaves hidden.

The Same Pressure Appears in Other Home Health Cases

Carter Healthcare’s Florida therapy settlement addressed allegations that unnecessary therapy and inaccurate assessments increased reimbursement from 2014 through 2016. It illustrates how the assessment and the volume of care can serve the same alleged payment objective.

A separate whistleblower complaint against Amedisys described pressure to keep patients on service. Its allegation puts the recertification decision in unusually blunt terms:

Everyone stays. That is the demand alleged in the Amedisys complaint, with the patient’s need for continued care pushed aside. Intrepid’s own settlement identifies the same underlying tension through its extended-care allegations: the decision about continuing treatment allegedly served reimbursement. An insider’s knowledge of who made that decision, and why, can give the clinical records their meaning.

You Know Why the Visits Continued

If you saw therapy or continued care driven by billing goals, tell our whistleblower experts what happened inside the agency. We work with you to build the case around the clinical decisions, the instructions behind them and the Medicare claims, bringing in home health fraud whistleblower lawyers who understand those connections. We stay with you through the whole journey, using your knowledge of the care to shape your strongest home health whistleblower case.